

Effective Monday March 24, 2025, ACL Laboratories implemented changes to Myeloproliferative Neoplasms (MPN) (Test Order Code LAB12257) billing.

Providers will need to select the appropriate testing pathway for **Polycythemia Vera (PV)** OR **Essential Thrombocythemia (ET)/Primary Myelofibrosis (PMF)** at the time of order entry. This step is essential to ensure the correct CPT charges are applied and prevents insurance denials. A detailed workflow layout is provided below.

- **Primary charge:** JAK2 (V617F) Mutation (CPT 81270) will be used for prior authorization workflow
- **Polycythemia Vera (PV) pathway:** JAK2 (V617F) Mutation (CPT 81270) with reflex to JAK2 Exon 12-15 Mutations Detection (CPT 81279)
- **Essential Thrombocythemia (ET)/Primary Myelofibrosis (PMF) pathway:** JAK2 (V617F) Mutation (CPT 81270) with reflex to CALR (Calreticulin) Exon 9 Mutations (CPT 81219), and MPL Exon 10 Mutations Detection (CPT 81339)

JAK2 (V617F) Mutation results will include quantitative results (VAF%) when detected. This change is intended to eliminate insurance denials. Previously used 81479 CPT will be discontinued.

If you have any questions or need additional information, please contact ACL Client Services at 800-877-7016.

